Zobrazeno 1 - 10
of 60
pro vyhledávání: '"L. Gianni"'
Autor:
Gerardo Rosati, Sara Lonardi, Fabio Galli, Maria Di Bartolomeo, Monica Ronzoni, Maria G. Zampino, Maria Banzi, Alberto Zaniboni, Felice Pasini, Silvia Bozzarelli, Silvio K. Garattini, Daris Ferrari, Vincenzo Montesarchio, Andrea Mambrini, Libero Ciuffreda, Francesca Galli, Valeria Pusceddu, Chiara Carlomagno, Paolo Bidoli, Domenico Amoroso, Anna M. Bochicchio, Luca Frassineti, Domenico Corsi, Domenico Bilancia, Alessandro Pastorino, Alfonso De Stefano, Roberto Labianca, D. Bilancia, G. Rosati, V. Montesarchio, R.V. Iaffaioli, G. Nasti, B. Daniele, V. Zagonel, S. Lonardi, N. Pella, G. Aprile, F. Pasini, Roma P. Marchetti, A. Romiti, L. Ciuffreda, D. Ferrari, P. Foa, A. Zaniboni, R. Labianca, S. Mosconi, A. Sobrero, P. Bidoli, M. Cazzaniga, G.D. Beretta, D.C. Corsi, E. Cortesi, S. Barni, F. Petrelli, P. Allione, A.M. D'Arco, G. Valmadre, E. Piazza, E. Veltri, G. Vietti Ramus, L. Giustini, S. Tumulo, S. Cascinu, C. Granetto, F. Testore, M. Giordano, M. Moroni, M. Di Seri, A. Nuzzo, L. Angelelli, S. Gori, G. Farina, M. Aglietta, R. Franchi, M. Comandé, P. Giordani, G. Tonini, E. Bucci, A. Ballestrero, M. Benasso, C. Graiff, S. Bravi, O. Caffo, R.R. Silva, L. Frontini, S. Rota, L. Cozzi, M. Cantore, E. Maiello, S. Cinieri, N. Silvestris, S. Romito, V. Gebbia, M. Banzi, A. Santoro, F. Artioli, R. Mattioli, A. Contu, F. Di Costanzo, F. Leonardi, L. Cavanna, R. Passalacqua, D. Amoroso, P. Sozzi, M. D'Amico, D. Amadori, L. Frassineti, D. Turci, A. Ravaioli, E. Pasquini, A. Gambi, M. Faedi, G. Cruciani, E. Bajetta, M. Di Bartolomeo, L. Gianni, M. Ronzoni, M.T. Ionta, B. Massidda, M. Scartozzi, M.G. Zampino, A.M. Bochicchio, A. Ciarlo, A. Di Leo, S. Frustaci, G. Rangoni, A. Arizzoia, L. Pavesi, C. Verusio, G. Pinotti, A. Iop, S. De Placido, C. Carlomagno, V. Adamo, C. Ficorella, D. Natale, E. Greco, E. Rulli, F. Galli, D. Poli, L. Porcu, V. Torri
Background: Previous studies on oxaliplatin and fluoropyrimidines as adjuvant therapy in older patients with stage III colon cancer (CC) produced conflicting results. Patients and methods: We assessed the impact of age on time to tumour recurrence (T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68fe67a06214c156899f253a2fbfbb53
https://hdl.handle.net/10281/401680
https://hdl.handle.net/10281/401680
Autor:
Rudolf Maibach, Roswitha Kammler, A. Di Leo, A. S. Coates, Kathryn P. Gray, L. Gianni, Harriet Johansson, Silvia Dellapasqua, G. Viale, Meredith M. Regan, R. D. Gelber, A. Goldhirsch, Manuela Rabaglio-Poretti, Claudio Zamagni, Elisabetta Munzone, M.A. Colleoni
Publikováno v:
Cancer Research. 78:P1-10
Background: Neoadjuvant endocrine therapy (NET) with gonadotropin-releasing hormone (GnRH) agonist and aromatase inhibitors is effective in selected premenopausal patients (pts). Degarelix, an antagonist of GnRH, has immediate onset of action through
Autor:
M Schmidt, M. Campone, JT Beck, Giancarlo Bianchi, L. Gianni, P Chen, Jasgit C. Sachdev, Claudio Zamagni, Noelia Martínez-Jañez, J. Miller, A Fandi, J. Cortes
Publikováno v:
Cancer Research. 78:P1-10
Background: Most patients diagnosed with breast cancer have ER+ tumors. Treatment of ER+ MBC typically involves endocrine therapy, including aromatase inhibitors and selective ER modulators such as tamoxifen; however, many patients develop resistance
Autor:
Lowell L. Hart, Maureen E. Trudeau, Frankie A. Holmes, Laura Biganzoli, TA Traina, D Markova, Vandana G. Abramson, Iulia Cristina Tudor, Ahmad Awada, Patrick G. Morris, L. Gianni, Ayca Gucalp, Steve Chan, EP Winer, R Stewart, Claudio Zamagni, Ian E. Krop, E Barry, D. A. Yardley, Joyce Steinberg, D Wheatley, M.A. Colleoni, J Tarazi, Laura G. Estévez, Lee S. Schwartzberg
Publikováno v:
Cancer Research. 78:GS4-07
Background: The androgen receptor (AR) is expressed in >75% of hormone receptor (HR)+ tumors. AR signaling has been associated with resistance to endocrine therapy (ET). Aromatase inhibitors (AIs) divert estrogen precursors to androgens; in preclinic
Autor:
M. Dugo, B. Gyorffy, G. Bisagni, M.A. Colleoni, M. Mansutti, C. Zamagni, L. Del Mastro, S. Zambelli, A. Frassoldati, L. Licata, B. Galbardi, O.M. Biasi, L. Viganò, A. Locatelli, G. Viale, P. Valagussa, M. Callari, L. Gianni, G. Bianchini
Publikováno v:
Annals of Oncology. 32:S421
Autor:
Gabriella Mariani, Stefania Zambelli, L. Del Mastro, E.M. Ciruelos, Giulia Viale, Stefania Russo, Begoña Bermejo, C-S Huang, L. Gianni, P. Valagussa, Chanel Smart, Giampaolo Bianchini, Marc Thill, Vladimir Semiglazov, Catherine M. Kelly, M.A. Colleoni, Antonio Antón, Claudio Zamagni, Richard Greil, Daniel Egle
Publikováno v:
Annals of Oncology. 31:S1145-S1146
Autor:
A. Lluch, Brigitte Poirier, Giampaolo Bianchini, Giancarlo Bianchi, Jose Luiz Pedrini, J. de la Haba-Rodríguez, P. Valagussa, Vladimir Semiglazov, Tadeusz Pienkowski, M-C Liu, D-Y. Oh, L-M Tseng, L. Gianni, Y-H Im
Publikováno v:
Cancer Research. 77:P1-09
Background: Patients (pts) with residual disease (RD) after neoadjuvant therapy are at higher risk of relapse. We investigated whether biomarkers assessed at surgery in patients pts with RD in the NeoSphere study were informative for risk of distant
Autor:
Steve Chan, Andrew M Wardley, Maureen E. Trudeau, L. Gianni, Maggie Liosatos, Kurt Miller, Ian E. Krop, J Sugg, M.T. Huizing, Joyce Steinberg, Louise Provencher, J. Cortes, VE Paton, Amy C. Peterson
Publikováno v:
Cancer Research. 77:P4-22
Background:Androgen receptor (AR) expression has been observed in up to 77% of human epidermal growth factor receptor 2–positive (HER2+) breast cancer (BC).References:1 Enzalutamide (ENZA) is a potent AR inhibitor approved for patients (pts) with m
Autor:
I Krop, V Abramson, M Colleoni, FA Holmes, L Estevez, L Hart, A Awada, C Zamagni, P Morris, L Schwartzberg, S Chan, D Wheatley, A Guculp, L Biganzoli, J Steinberg, L Gianni, M Trudeau, CM Kelly, H Uppal, IC Tudor, A Peterson, E Winer, DA Yardley
Publikováno v:
Cancer Research. 77:P2-08
This abstract was withdrawn by the authors.
Autor:
L. Gianni, Claudio Zamagni, P. Valagussa, L. Del Mastro, Antonio Frassoldati, M. Mansutti, Giulia Viale, M.A. Colleoni, R De Fato, Milvia Zambetti, Giancarlo Bisagni
Publikováno v:
Cancer Research. 77:P4-21
Background: In metastatic breast cancer, the CDK4,6 inhibitor palbociclib associated with fulvestrant proved superior to fulvestrant alone in HER2-negative breast cancer (NEJM 2015). In HER2-positive tumors, the dual blockade of the receptor plus an